Abstract |
Among risk factors for developing thromboembolism (VTE) in children with acute lymphoblastic leukemia were Escherichia coli asparaginase, concomitant steroid use, presence of central venous lines, and thrombophilic abnormalities. Developing a predictive model for determining children at increased risk would be beneficial in targeting interventional studies to high-risk groups (HRGs). Predictive variables were incorporated into a risk assessment model, which was evaluated in 456 children and then validated in 339 patients. VTE risk by score was no greater than 2.5 for low-risk group (LRG) and greater than 2.5 for HRG. VTE rates at 3.5 months (validation cohorts) were 2.5% in LRG and 64.7% in HRG. In multivariate analysis adjusted for age, duration of asparaginase administration, enoxaparin prophylaxis, and T-immunophenotype, the HRG was significantly associated with VTE compared with the LRG (hazard/95% confidence interval [CI], 8.22/1.85-36.53). Model specificity was 96.2% and sensitivity was 63.2%. As secondary objective we investigated the use of enoxaparin for VTE prophylaxis in the HRG. HRG patients without enoxaparin prophylaxis showed a significantly reduced thrombosis-free survival compared with children on low-molecular-weight heparin ( LMWH). On the basis of the high specificity, the model may identify children with leukemia at risk of VTE. LMWH may help prevent VTE in the HRG; this warrants assessment in larger cooperative clinical trials.
|
Authors | Lesley Mitchell, Moritz Lambers, Silke Flege, Gili Kenet, Valerie Li-Thiao-Te, Susanne Holzhauer, Christoph Bidlingmaier, Michael C Frühwald, Christine Heller, Wolfgang Schmidt, Brigitte Pautard, Ulrike Nowak-Göttl |
Journal | Blood
(Blood)
Vol. 115
Issue 24
Pg. 4999-5004
(Jun 17 2010)
ISSN: 1528-0020 [Electronic] United States |
PMID | 20339086
(Publication Type: Journal Article, Multicenter Study, Validation Study)
|
Chemical References |
- Anticoagulants
- Enoxaparin
- Steroids
- Asparaginase
|
Topics |
- Adolescent
- Anticoagulants
(therapeutic use)
- Asparaginase
(therapeutic use)
- Catheterization, Central Venous
(statistics & numerical data)
- Child
- Child, Preschool
- Cohort Studies
- Databases, Factual
- Enoxaparin
(therapeutic use)
- Humans
- Infant
- Models, Statistical
- Multivariate Analysis
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(epidemiology)
- Predictive Value of Tests
- Reproducibility of Results
- Risk Assessment
(methods)
- Risk Factors
- Sensitivity and Specificity
- Steroids
(therapeutic use)
- Thromboembolism
(diagnosis, epidemiology, prevention & control)
|